Tirlán Equity Placement and Off Market Purchase

Summary by AI BETAClose X

Glanbia plc has announced that Tirlán Co-operative Society Limited intends to sell approximately 5.00% of Glanbia's issued share capital through an equity placement to institutional investors and an off-market purchase by Glanbia of shares up to EUR 50 million. This off-market purchase will utilize the remaining authorized EUR 50 million of Glanbia's EUR 100 million share buyback program, with the consideration for these shares to be determined by the price set in the equity placement. Glanbia confirms it has no unpublished inside information.

Disclaimer*

Glanbia PLC
11 June 2026
 

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION

Glanbia plc

Statement on Tirlán Equity Placement and Off Market Purchase

Glanbia plc, the Better Nutrition company ("Glanbia" or the "Company"), has been informed by Tirlán Co-operative Society Limited ("Tirlán") that it intends to sell approximately 12 million ordinary shares in the capital of Glanbia by way of:

1.   a private placement to institutional investors to be executed through an accelerated bookbuild offering process (the "Equity Placement"); and

2.   an off-market sale by Tirlán to the Company of shares up to an aggregate value of EUR 50 million (the "Off Market Purchase"") pursuant to the directed buyback contract (the "Directed Buyback Contract") between the Company and Tirlán approved by shareholders at the annual general meeting of the Company held on 29 April 2026 (the "2026 AGM"),

(together, the "Transaction").

The Off-Market Purchase will be conducted within the limits of the Company's authority to repurchase shares off market, as set out in Resolution 13 approved by shareholders at the 2026 AGM, in conjunction with, and conditional upon, the completion of the Equity Placement. Any shares purchased by the Company pursuant to the Directed Buyback Contract will be cancelled.

The consideration for the Off-Market Purchase will, in accordance with the Directed Buyback Contract, be determined by reference to the price established through the bookbuilding process in the Equity Placement.

The shares subject to the Transaction represent approximately 5.00% of Glanbia's issued share capital.

On 25 February 2026, the Company announced that the Board had approved a €100 million share buyback programme, of which €50 million was commenced on the same date. The €50 million programme which commenced on 25 February 2026 remains ongoing. The Off-Market Purchase will utilise the remaining €50 million of the authorised €100 million buyback programme.

Goodbody Stockbrokers UC ("Goodbody") and Coöperatieve Rabobank U.A. in cooperation with Kepler Cheuvreux S.A. ("Rabobank-Kepler Cheuvreux") are acting as joint global coordinators and joint bookrunners in connection with the Equity Placement (Goodbody and Rabobank-Kepler Cheuvreux together the "Joint Global Coordinators").

The Company confirms that it currently has no unpublished inside information.

Further details of the Off-Market Purchase, including the number of shares acquired and the price per share, will be published following completion of the Transaction.

 

ENDS

 

For further information contact:

Glanbia plc                                                                                                +353 56 777 2200

Mark Garvey, Chief Financial Officer

Liam Hennigan, Group Secretary & Head of Investor Relations:               +353 86 046 8375

Martha Kavanagh, Director of Corporate Affairs:                                       +353 87 646 2006

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings